2016
DOI: 10.1200/jco.2016.34.15_suppl.e21020
|View full text |Cite
|
Sign up to set email alerts
|

Descriptive analysis of the use of ipilimumab (IPI) in previously treated patients with unresectable stage III or IV metastatic melanoma (MM) in four university hospitals of Quebec, Canada.

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles